Avi B. Markowitz

1.5k total citations
35 papers, 1.1k citations indexed

About

Avi B. Markowitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Avi B. Markowitz has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Avi B. Markowitz's work include Immunotherapy and Immune Responses (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Treatment and Pharmacology (4 papers). Avi B. Markowitz is often cited by papers focused on Immunotherapy and Immune Responses (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Treatment and Pharmacology (4 papers). Avi B. Markowitz collaborates with scholars based in United States, Finland and Spain. Avi B. Markowitz's co-authors include Catherine M. Broome, Maha Hussain, David J. Vaughn, John Gutheil, Avishay Sella, Jae Y. Ro, James L. Abbruzzese, David Parkinson, N. Ciobanu and Geoffrey R. Weiss and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Avi B. Markowitz

34 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Avi B. Markowitz United States 16 561 383 377 245 220 35 1.1k
Simona Secondino Italy 18 687 1.2× 227 0.6× 168 0.4× 206 0.8× 261 1.2× 59 1.2k
Jacob R. Izbicki Germany 18 576 1.0× 357 0.9× 394 1.0× 284 1.2× 92 0.4× 47 1.3k
O. Thetter Germany 21 681 1.2× 1.3k 3.3× 414 1.1× 276 1.1× 106 0.5× 64 2.0k
Jin-Hyuk Choi South Korea 13 433 0.8× 752 2.0× 362 1.0× 196 0.8× 61 0.3× 18 1.2k
Yabing Cao China 15 350 0.6× 135 0.4× 131 0.3× 191 0.8× 144 0.7× 52 811
H. J. Wanebo United States 16 1.1k 1.9× 938 2.4× 678 1.8× 214 0.9× 68 0.3× 33 1.9k
K. Bertelsen Denmark 25 849 1.5× 296 0.8× 1.1k 2.9× 181 0.7× 77 0.3× 70 2.3k
Bernard R. Greenberg United States 19 554 1.0× 238 0.6× 143 0.4× 206 0.8× 203 0.9× 64 1.5k
Tong-Yu Lin China 22 586 1.0× 163 0.4× 141 0.4× 444 1.8× 237 1.1× 47 1.3k
D. Pectasides Greece 21 590 1.1× 293 0.8× 361 1.0× 299 1.2× 86 0.4× 55 1.3k

Countries citing papers authored by Avi B. Markowitz

Since Specialization
Citations

This map shows the geographic impact of Avi B. Markowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avi B. Markowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avi B. Markowitz more than expected).

Fields of papers citing papers by Avi B. Markowitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avi B. Markowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avi B. Markowitz. The network helps show where Avi B. Markowitz may publish in the future.

Co-authorship network of co-authors of Avi B. Markowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Avi B. Markowitz. A scholar is included among the top collaborators of Avi B. Markowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avi B. Markowitz. Avi B. Markowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weiser, Roi, Efstathia Polychronopoulou, Waqar Haque, et al.. (2021). Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases: An NCDB Analysis. Annals of Surgical Oncology. 28(13). 8717–8727. 5 indexed citations
2.
3.
Markowitz, Avi B., et al.. (2012). Rituximab. BioDrugs. 26(2). 71–82. 12 indexed citations
4.
Weber, Michael A., Henry R. Black, Rafaël Fonseca, et al.. (2012). Association of Clinical Researchers and Educators A Statement on Relationships Between Physicians and Industry. Endocrine Practice. 18(6). 1029–1037. 1 indexed citations
5.
Markowitz, Avi B., et al.. (2008). Knowledge of Indications and Utilization of EUS. Journal of Clinical Gastroenterology. 42(8). 892–896. 17 indexed citations
6.
Wang, Jue, Yong Fang Kuo, Jean L. Freeman, Avi B. Markowitz, & James S. Goodwin. (2007). Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer. 112(2). 382–390. 11 indexed citations
7.
8.
Pazdur, Richard, J. L. Abbruzzese, Avi B. Markowitz, et al.. (1995). Phase II Trial of Isotretinoin and Recombinant Interferon Alfa-2a in Metastatic Colorectal Carcinoma. American Journal of Clinical Oncology. 18(5). 436–438. 2 indexed citations
9.
Pazdur, Richard, Yvonne Lassere, Verna A. Rhodes, et al.. (1994). Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.. Journal of Clinical Oncology. 12(11). 2296–2300. 170 indexed citations
10.
Carrasco, C. H., David Lawrence, William R. Richli, et al.. (1993). Intraperitoneal Catheters: Percutaneous Placement with Fluoroscopic Guidance. Journal of Vascular and Interventional Radiology. 4(2). 299–304. 6 indexed citations
11.
Danhauser, L, et al.. (1993). Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.. Journal of Clinical Oncology. 11(4). 751–761. 31 indexed citations
12.
Dimopoulos, Meletios Α., C. Logothetis, Avi B. Markowitz, et al.. (1993). Collecting Duct Carcinoma of the Kidney. British Journal of Urology. 71(4). 388–391. 100 indexed citations
13.
Wetzler, Meir, Zeev Estrov, Moshe Talpaz, et al.. (1993). Granulocyte‐macrophage colony‐stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. Journal of Internal Medicine. 234(4). 417–420. 35 indexed citations
14.
Ajani, Jaffer A., et al.. (1993). Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Investigational New Drugs. 11(1). 67–69. 2 indexed citations
15.
Schilling, Paul J., et al.. (1992). Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction. Cancer. 69(1). 256–260. 28 indexed citations
16.
Markowitz, Avi B., et al.. (1991). Cytokines and chemotherapy: A new approach to therapy for solid tumors. 43(3). 224–232. 2 indexed citations
17.
Hayakawa, Kazuhiro, David Parkinson, Avi B. Markowitz, et al.. (1991). Study of Tumor-Infiltrating Lymphocytes for Adoptive Therapy of Renal Cell Carcinoma (RCC) and Metastatic Melanoma: Sequential Proliferation of Cytotoxic Natural Killer and Noncytotoxic T Cells in RCC. Journal of Immunotherapy. 10(5). 313–325. 21 indexed citations
18.
Hudson, Melissa M., et al.. (1990). Effect of recombinant human interleukin 4 on human monocyte activity.. PubMed. 50(11). 3154–8. 20 indexed citations
19.
Parkinson, David, Moshe Talpaz, Sewa S. Legha, et al.. (1989). Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center. Cancer Treatment Reviews. 16. 39–48. 7 indexed citations
20.
Dutcher, Janice P., Stephen P. Creekmore, Geoffrey R. Weiss, et al.. (1989). A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.. Journal of Clinical Oncology. 7(4). 477–485. 180 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simona Secondino Breakdown of academic impact, for papers by Jacob R. Izbicki Breakdown of academic impact, for papers by O. Thetter Breakdown of academic impact, for papers by Jin-Hyuk Choi Breakdown of academic impact, for papers by Yabing Cao Breakdown of academic impact, for papers by H. J. Wanebo Breakdown of academic impact, for papers by K. Bertelsen Breakdown of academic impact, for papers by Bernard R. Greenberg Breakdown of academic impact, for papers by Tong-Yu Lin Breakdown of academic impact, for papers by D. Pectasides
Rankless by CCL
2026